Forget GlaxoSmithKline! 2 ‘better’ pharmaceutical stocks I think could help you retire in luxury

Sure, GlaxoSmithKline plc (LON: GSK) has delivered some pretty decent shareholder returns over the past half a decade. But are these other medical marvels better buys today?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

There’s a hell of a lot to like about GlaxoSmithKline (LSE: GSK) from an investment point of view. It’s always been committed to paying juicy, inflation-busting dividends, even when patent expirations on superstar labels put the boot into the bottom line. Indeed, in spite of some quite severe earnings turbulence in recent years it’s still kept the annual payout locked at 80p per share since 2014 and is expected to shell out similar payouts in 2019 and 2020.

Consequently, Glaxo shareholders can drink in a dividend yield of 4.7% through this period, a chubby reading which beats the broader FTSE 100 forward average by a nose. And it’s probable that investor payouts will get increasingly juicy beyond the medium term as its pipeline of new medicines keeps on delivering (it currently has 44 in development).

A better buy?

But is Glaxo the best pharmaceuticals play you can get hold of right now? Total shareholder returns (including reinvested dividends) for the firm come in at 47% for the past five years.

By comparison, returns at Dechra Pharmaceuticals (LSE: DPH) clock in at 344.1% over the same period. Sure, those aforementioned patent issues may have hampered Glaxo’s run of late, but Dechra’s far superior record illustrates in large part the scintillating growth outlook for the animal care market that’s seen buyers piling in en masse.

Healthcare for livestock and companion animals is increasingly big business, as recent data from Zion Market Research shows. It estimates the animalcare market will grow by more $11bn over the seven years to 2024 to total a colossal $41.8bn.

It’s little wonder, then, that Dechra saw group revenues bloom 17% in the 12 months to June, a result underpinned by its massive acquisition programme of the past decade which has greatly boosted its product stable and geographic footprint.

City analysts expect earnings at the FTSE 250 firm to swell an extra 14% in the new fiscal year, keeping Dechra’s strong record of double-digit annual increases in business. And it’d be a brave man who bets that profits won’t continue booming beyond the near term.

Another top buy

I also reckon UDG Healthcare (LSE: UDG) has what it takes to keep delivering cosmic shareholder gains in the years ahead. It’s generated a total return of 144% in the past half a decade and is likely to keep pleasing investors as global drugs demand booms.

You see, UDG is involved in a broad array of health-related services, from providing advertising and advisory services to the medical industry, through to manufacturing and packaging drug products. And with the worldwide healthcare budget growing — driven by North America and Asian emerging markets — and an increasing-elderly population driving the number of age-related diseases steadily higher, the long-term demand outlook for this company looks pretty bright.

Like Dechra, UDG has also delivered some meaty profits increases in recent years. And after a predicted 5% rise for the 12 months ending September 2019 it’s expected to pick up the pace again with an 11% increase in the following fiscal year. And, like the animalcare specialist, UDG has the financial firepower to keep engaging in top acquisitions to drive business too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended UDG Healthcare. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Retirement Articles

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how I’m using my ISAs to target retirement riches

A comfortable retirement's on my mind and I'm using my ISAs to help me get there. But while my cash…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

134,000 reasons why I prefer FTSE 100 stocks over cash savings!

The results are in! Investing in FTSE 100 stocks can be a superior way to build wealth than saving, as…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

What sort of shares can make sense to buy for a SIPP?

Thinking about the right shares to buy for a SIPP can involve a long-term view and some self-awareness. Here, our…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

No savings at 40? Here are 3 steps to target a comfortable retirement with UK shares

A well-balanced and tax-efficient portfolio of UK and US shares can build a substantial pension pot, as Royston Wild explains.

Read more »

Group of friends talking by pool side
Investing Articles

This SIPP strategy turned £5,000 into a small fortune! Could it work again?

Want to grow a SIPP investment portfolio by six times? Zaven Boyrazian explores a strategy that’s delivered enormous returns when…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

Want to become an ISA millionaire? Here’s one way to target stock market riches with £500 a month

Making a million pounds or more in an ISA doesn't have to be a pipe dream. Here's how a mix…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

3 techniques to turbocharge your SIPP for a richer retirement!

Christopher Ruane considers a trio of ways he thinks an investor could use to try and grow the long-term value…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

Forget the State Pension! Here’s how to target a comfortable retirement income with £500 a month

The British State Pension is nowhere near enough money to enjoy a comfortable retirement today. Here's what investors can do…

Read more »